Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Nanjing Leads Biolabs Co., Ltd. Class H ( (HK:9887) ).
Nanjing Leads Biolabs Co., Ltd. announced that its self-developed drug, LBL-047, has received Investigational New Drug (IND) approval from the U.S. FDA. LBL-047 is a bispecific fusion protein targeting BDCA2 and TACI, showing first-in-class potential for treating autoimmune diseases such as systemic lupus erythematosus and Sjögren’s syndrome. This approval marks a significant milestone for the company, potentially enhancing its market position and offering new therapeutic options for patients with autoimmune conditions.
The most recent analyst rating on (HK:9887) stock is a Buy with a HK$80.27 price target. To see the full list of analyst forecasts on Nanjing Leads Biolabs Co., Ltd. Class H stock, see the HK:9887 Stock Forecast page.
More about Nanjing Leads Biolabs Co., Ltd. Class H
Nanjing Leads Biolabs Co., Ltd. is a joint stock company based in China, operating in the biopharmaceutical industry. The company focuses on developing innovative drugs, with a particular emphasis on autoimmune diseases.
Average Trading Volume: 2,105,302
For an in-depth examination of 9887 stock, go to TipRanks’ Overview page.